Reading TRDA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TRDA free→Reading TRDA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TRDA free→QuarterlyIQ Insights · TRDA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. On June 10, 2026, Entrada Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format via live webcast. As further described under
of this Form 8-K shall be deemed to be furnished and not filed: 99.1 Press Release issued by Entrada Therapeutics, Inc. on May 7 , 2026 99.2 Press Release issued by Entrada Therapeutics, Inc. on May 7, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entrada Therape…
Results of Operations and Financial Condition. On February 26, 2026, Entrada Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes…
Other Events. On January 8, 2026, the Company reported its progress across its portfolio of RNA-based therapeutics for the treatment of neuromuscular and ocular diseases. The Company completed dosing of Cohort 1 of the global Phase 1/2 multiple ascending dose (MAD) portion of the clinical study of ENTR-601-44 in ambulatory patients living with DMD who are amenable to exon 44 skipping, and transitioned to the open label, Phase 2 portion of the study. The Company is on track to report ELEVATE-4…
of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Results of Operations and Financial Condition. On November 6, 2025, Entrada Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes…
Results of Operations and Financial Condition. On August 6, 2025, Entrada Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Sect…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 30, 2025, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from six to seven directors and appointed Maha Radhakrishnan, M.D. to the Board as a Class III director, to serve until the Company’s annual meeting of stockholders to be held in 2027 or until her successor is duly elec…
Results of Operations and Financial Condition. On May 8, 2025, Entrada Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Sectio…
Costs Associated with Exit or Disposal Activities. On April 29, 2025, the board of directors of Entrada Therapeutics, Inc. (the “Company”) approved a strategic plan designed to increase the focus of the Company’s resources on its expanding portfolio of clinical candidates in Duchenne muscular dystrophy (“DMD”) and key preclinical programs. Effective May 2, 2025, the new strategic plan will include enhanced hiring efforts to support planned global clinical trial execution in DMD, as well as fo…
of this Form 8-K shall be deemed to be furnished and not filed: 99.1 Press Release issued by Entrada Therapeutics, Inc. on March 24 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entrada Therapeutics, Inc. Date: March 24, 2025 /s/ Dipal Doshi Dipal Doshi Chief E…
Other Events. On March 24, 2025, the Company announced the receipt of authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product for a Phase 1/2 multiple ascending dose (“MAD”) clinical study of ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (“DMD”) in patients with a confirmed mutation in the DMD gene amenable to exon 45 skipping. ENTR-601-45 i…
Results of Operations and Financial Condition. On February 27, 2025, Entrada Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2024 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes…
Other Events. On February 24, 2025, the Company announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and provided authorization for a Phase 1b multiple ascending dose clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (“DMD”) in non-ambulatory and ambulatory adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. ENTR-601-44 is Entrada’s lead product candidate within its D…
Other Events. On February 3, 2025, the Company announced the receipt of authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product for a Phase 1/2 multiple ascending dose clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (“DMD”) in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. ENTR-601-44 is Entr…
Results of Operations and Financial Condition. On January 15, 2025, Entrada Therapeutics, Inc. (the “Company”) presented at the 43 rd Annual J.P. Morgan Healthcare Conference, which presentation included certain preliminary financial results as of and for the fiscal year ended December 31, 2024. Specifically, the Company announced that its cash resources, which consist of cash, cash equivalents and marketable securities, were approximately $420.0 million as of December 31, 2024 and that it ex…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.